Skip to main content
. 2022 May 23;9:23743735221102678. doi: 10.1177/23743735221102678

Figure 1.

Figure 1.

Reasons for limited access to healthcare services/medications among rheumatic and musculoskeletal diseases (RMDs) patients during the COVID-19 pandemic (N = 120).